Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $196,277.41 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Alfred Ford, Jr. sold 8,681 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $22.61, for a total transaction of $196,277.41. Following the completion of the transaction, the insider directly owned 118,854 shares of the company’s stock, valued at approximately $2,687,288.94. The trade was a 6.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Up 5.1%

Shares of NASDAQ:KMTS traded up $1.16 during mid-day trading on Monday, reaching $23.99. 373,728 shares of the stock were exchanged, compared to its average volume of 404,856. The company has a market cap of $1.41 billion, a P/E ratio of -9.91 and a beta of 0.58. The stock’s 50 day simple moving average is $22.62 and its 200-day simple moving average is $22.48. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a one year low of $14.10 and a one year high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The business had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. As a group, equities research analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Seven Grand Managers LLC bought a new position in shares of Kestra Medical Technologies in the fourth quarter valued at about $2,652,000. Eventide Asset Management LLC boosted its holdings in shares of Kestra Medical Technologies by 5.4% during the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after buying an additional 65,288 shares during the period. Summit Partners Public Asset Management LLC acquired a new position in Kestra Medical Technologies in the 4th quarter valued at about $9,282,000. Jennison Associates LLC raised its holdings in Kestra Medical Technologies by 15.0% in the 4th quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock valued at $5,817,000 after acquiring an additional 28,573 shares during the period. Finally, UBS Group AG lifted its position in Kestra Medical Technologies by 34.9% during the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock worth $7,162,000 after acquiring an additional 69,908 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on KMTS shares. Oppenheimer started coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating on the stock. The Goldman Sachs Group dropped their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Finally, BTIG Research lifted their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Kestra Medical Technologies presently has an average rating of “Hold” and an average target price of $27.83.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.